RT Journal Article
SR Electronic
T1 EP1210 Follow-up in gynecologic malignancies, correspondence with ESGO Guidelines- preliminary result of ENYGO survey
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP A621
OP A623
DO 10.1136/ijgc-2019-ESGO.1247
VO 29
IS Suppl 4
A1 I Selcuk
A1 M Lanner
A1 A Pletnev
A1 D Vlachos
A1 T Nikolova
A1 D Lindquist
A1 K Zalewski
YR 2019
UL http://ijgc.bmj.com/content/29/Suppl_4/A621.3.abstract
AB Introduction/Background To identify the follow-up strategies of gynecologic malignancies across Europe and compare the correspondence with ESGO Guidelines.Methodology In 2019, a web-based survey was sent to the National Representatives of European Network of Young Gynae-Oncologists (2017–2019). The questionnaire consists of the questions related with vulvar cancer, cervical cancer, endometrial cancer and ovarian cancer.Results A total of 15/31 (48.3%) National Representatives responded the survey. Despite having a national guideline (>50%), the topic of follow-up was missing in some countries. The follow-up was mainly led by clinicians and performed by gynecologic oncology team (table 1). For each malignancy, gynecologic examination is performed at every visit. Responders stated that Pap-test is routinely performed during the follow-up of cervical cancer 8/8 (100.0%), additionally in endometrial cancer 4/7 (57.1%) of responders perform routine Pap-test. Serum Ca-125 level is never routinely preferred during the follow-up of endometrial cancer, however serum Ca-125 is mostly preferred routinely for ovarian cancer. Complete blood count-biochemical tests and chest X-ray are not routine tests to consider at every visit. Routine imaging is mostly preferred for ovarian cancer and computed tomography is the most common imaging technique in case of a suspicion of recurrence except vulvar cancer in which magnetic resonance imaging is preferred (table 2).Conclusion This preliminary results indicated that follow-up periods are similar with ESGO Guidelines. One of the major differences is that cytology is not recommended after radical/simple hysterectomy or chemoradiation in cervical cancer and the other one is serum Ca-125 is not a reliable marker in non-High grade serous carcinoma of the ovary. ESGO Guidelines generally don't recommend routine imaging unless a clinically indicated situation. Finally, these preliminary results showed that majority of the responses are similar with ESGO Guidelines.Disclosure Nothing to discloseView this table:Abstract EP1210 Table 1 Follow-up methods and periods for vulvar, cervical, endometrial and ovarian cancerView this table:Abstract EP1210 Table 2 Performed procedures at every visit for vulvar, cervical, endometrial and ovarian cancer